Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
ligelizumab - IgE inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04210843 (CQGE031C2302E1)
Chronic spontaneous urticaria
Phase 3
1520
The proportion of subjects with well-controlled disease (UAS7 ? 6) at week 12
Ligelizumab Dose 1 and 3
Ligelizumab Dose 2 and 3
Patients who completed studies CQGE031C2302, CQGE031C2303,
CQGE031C2202 or CQGE031C1301
Target Patients
Read-out Milestone(s)
2026
Publication
Study design presented at 2020 EAACI
89 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation